The digital era opens up the field of possibilities: web, e-mail, networks, optical fingerprints, digital storage... It will then be possible to optimize the use of the digital tool for both data collection and storage, information transfer, restitution, implementation of electronic signature, preservation of digital model... However, it must not alter the practitioner's care for his patients. Indeed, securing patients' medical data is an integral part of their care. Even if it is immaterial, their protection as to be effective, even at the physical level. The aim of this article is to list our obligations towards the virtual tool, the management modalities to avoid any prejudice. The research of the texts was carried out on Legifrance, CNIL, Pubmed and the jurisprudence. The authorization to collect data and the possibility to transfer them to a third part is mandatory. The conservation of these data in adequate conditions, both physical and digital, is essential to avoid the loss of the data and the consequent sanctions. The security of medical data requires the protection of the premises, computers and the Internet tool. The implementation of regulated protocols is the only guarantee of data security and good faith in front of the judge in case of loss. It requires the involvement of the entire healthcare team to implement effective procedures.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1684/orthodfr.2021.31 | DOI Listing |
AIDS Patient Care STDS
January 2025
Department of Obstetrics, Gynecology & Reproductive Sciences, University of California San Francisco, Oakland, California, USA.
Community health workers (CHWs) play a significant role in supporting health services delivery in communities with few trained health care providers. There has been limited research on ways to optimize the role of CHWs in HIV prevention service delivery. This study explored CHWs' experiences with offering HIV prevention services [HIV testing and HIV pre- and post-exposure prophylaxis (PrEP and PEP)] during three pilot studies in rural communities in Kenya and Uganda, which aimed to increase biomedical HIV prevention coverage via a structured patient-centered HIV prevention delivery model.
View Article and Find Full Text PDFJAMA Netw Open
January 2025
Department of Global Health, School of Public Health, Boston University, Boston, Massachusetts.
Importance: Semaglutide, a novel glucagon-like peptide-1 (GLP-1) receptor agonist medication, was approved for weight management in individuals with obesity in June 2021. There is limited evidence on factors associated with uptake among individuals in this subgroup without diabetes.
Objective: To explore factors associated with semaglutide initiation among a population of commercially insured individuals with obesity but no diagnosed diabetes.
JAMA Netw Open
January 2025
Institute of Medical Science, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
Importance: Secondary lymphedema is a common, harmful side effect of breast cancer treatment. Robust risk models that are externally validated are needed to facilitate clinical translation. A published risk model used 5 accessible clinical factors to predict the development of breast cancer-related lymphedema; this model included a patient's mammographic breast density as a novel predictive factor.
View Article and Find Full Text PDFJ Travel Med
January 2025
UQ Centre for Clinical Research, Faculty of Health, Medicine, and Behavioural Sciences, The University of Queensland, Herston, Australia.
Background: Japanese encephalitis virus (JEV) is a leading cause of viral encephalitis in Asia, with high case-fatality rate and morbidity. Although the live recombinant Japanese encephalitis chimeric vaccine (Imojev®) offers strong initial immunity, data on long-term efficacy beyond five years remain limited.
Methods: We conducted a cross-sectional study on adults vaccinated with Imojev® at a specialist travel clinic in Brisbane, Australia.
JAMA Pediatr
January 2025
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Importance: Spontaneous reports have indicated that montelukast increases the risk of neuropsychiatric adverse events, and the US Food and Drug Administration added a boxed warning about these risks in 2020. However, the potential mechanism is not well understood, and the observational evidence is scarce, particularly in children.
Objective: To assess the potential association between the use of montelukast and the risk of neuropsychiatric adverse events in children and adolescents.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!